Vanguard Group Inc cut its stake in Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) by 1.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,247,144 shares of the biopharmaceutical company’s stock after selling 37,672 shares during the quarter. Vanguard Group Inc owned 4.19% of Tetraphase Pharmaceuticals worth $6,202,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Bank of New York Mellon Corp increased its stake in shares of Tetraphase Pharmaceuticals by 20.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 289,970 shares of the biopharmaceutical company’s stock valued at $1,035,000 after acquiring an additional 49,332 shares during the last quarter. Schwab Charles Investment Management Inc. increased its stake in shares of Tetraphase Pharmaceuticals by 9.2% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 275,630 shares of the biopharmaceutical company’s stock valued at $984,000 after acquiring an additional 23,337 shares during the last quarter. BlackRock Inc. increased its stake in shares of Tetraphase Pharmaceuticals by 3.7% in the 2nd quarter. BlackRock Inc. now owns 4,172,314 shares of the biopharmaceutical company’s stock valued at $14,895,000 after acquiring an additional 149,866 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in Tetraphase Pharmaceuticals by 20.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,200,413 shares of the biopharmaceutical company’s stock worth $7,855,000 after purchasing an additional 367,672 shares in the last quarter. Finally, Millennium Management LLC increased its stake in Tetraphase Pharmaceuticals by 129.7% during the 2nd quarter. Millennium Management LLC now owns 297,942 shares of the biopharmaceutical company’s stock worth $1,064,000 after purchasing an additional 168,253 shares in the last quarter. 42.90% of the stock is owned by institutional investors.

TTPH has been the subject of a number of research reports. Zacks Investment Research cut Tetraphase Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, October 17th. B. Riley initiated coverage on Tetraphase Pharmaceuticals in a research note on Friday, January 4th. They set a “buy” rating and a $3.00 target price for the company. Finally, Robert W. Baird reissued a “buy” rating and set a $3.00 target price on shares of Tetraphase Pharmaceuticals in a research note on Monday, January 7th. One analyst has rated the stock with a sell rating, three have given a hold rating and eight have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $5.36.

NASDAQ TTPH traded up $0.02 during trading hours on Monday, reaching $1.20. 35,432 shares of the company’s stock were exchanged, compared to its average volume of 579,037. The stock has a market cap of $63.28 million, a price-to-earnings ratio of -0.46 and a beta of 2.89. Tetraphase Pharmaceuticals Inc has a one year low of $1.01 and a one year high of $5.68.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last issued its quarterly earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.02). The business had revenue of $1.15 million for the quarter, compared to the consensus estimate of $2.09 million. Tetraphase Pharmaceuticals had a negative return on equity of 65.89% and a negative net margin of 432.40%. Analysts anticipate that Tetraphase Pharmaceuticals Inc will post -1.33 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Tetraphase Pharmaceuticals Inc (TTPH) Stake Lowered by Vanguard Group Inc” was originally reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this article on another site, it was copied illegally and republished in violation of international trademark & copyright law. The original version of this article can be accessed at https://theolympiareport.com/2019/02/11/tetraphase-pharmaceuticals-inc-ttph-stake-lowered-by-vanguard-group-inc.html.

About Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is eravacycline, a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.

Featured Story: Momentum Indicator: Relative Strength Index

Institutional Ownership by Quarter for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.